CA2291471A1 - Diminution des concentrations de lipoproteine(a) dans le sang - Google Patents

Diminution des concentrations de lipoproteine(a) dans le sang Download PDF

Info

Publication number
CA2291471A1
CA2291471A1 CA002291471A CA2291471A CA2291471A1 CA 2291471 A1 CA2291471 A1 CA 2291471A1 CA 002291471 A CA002291471 A CA 002291471A CA 2291471 A CA2291471 A CA 2291471A CA 2291471 A1 CA2291471 A1 CA 2291471A1
Authority
CA
Canada
Prior art keywords
secretion
pharmaceutical composition
amide
carboxylic acid
lipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002291471A
Other languages
English (en)
Inventor
George Chang
Ernest Seiichi Hamanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CA2291471A1 publication Critical patent/CA2291471A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002291471A 1998-12-04 1999-12-02 Diminution des concentrations de lipoproteine(a) dans le sang Abandoned CA2291471A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11110098P 1998-12-04 1998-12-04
US60/111,100 1998-12-04

Publications (1)

Publication Number Publication Date
CA2291471A1 true CA2291471A1 (fr) 2000-06-04

Family

ID=22336605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002291471A Abandoned CA2291471A1 (fr) 1998-12-04 1999-12-02 Diminution des concentrations de lipoproteine(a) dans le sang

Country Status (6)

Country Link
JP (1) JP2000169395A (fr)
KR (1) KR20000047857A (fr)
CA (1) CA2291471A1 (fr)
HU (1) HUP9904485A3 (fr)
IL (1) IL133201A0 (fr)
ZA (1) ZA997446B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432392B2 (en) 2003-08-29 2008-10-07 Japan Tobacco Inc. Ester derivatives and medical use thereof
US7625948B2 (en) 2002-02-28 2009-12-01 Japan Tobacco Inc. Ester compound and medicinal use thereof
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2324801A1 (fr) * 1999-11-10 2001-05-10 Andrew Gordon Swick Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp et d'agents contre l'obesite
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
IL139449A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Use of apo b secretion/mtp inhibitors
CA2324800A1 (fr) * 1999-11-10 2001-05-10 Mary Anne Hickman Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625948B2 (en) 2002-02-28 2009-12-01 Japan Tobacco Inc. Ester compound and medicinal use thereof
US7432392B2 (en) 2003-08-29 2008-10-07 Japan Tobacco Inc. Ester derivatives and medical use thereof
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US8618135B2 (en) 2004-03-05 2013-12-31 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US9265758B2 (en) 2004-03-05 2016-02-23 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US9364470B2 (en) 2004-03-05 2016-06-14 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US9433617B1 (en) 2004-03-05 2016-09-06 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US9861622B2 (en) 2004-03-05 2018-01-09 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US10016404B2 (en) 2004-03-05 2018-07-10 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US10555938B2 (en) 2004-03-05 2020-02-11 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US11554113B2 (en) 2004-03-05 2023-01-17 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof

Also Published As

Publication number Publication date
KR20000047857A (ko) 2000-07-25
HUP9904485A3 (en) 2000-09-28
IL133201A0 (en) 2001-03-19
JP2000169395A (ja) 2000-06-20
HUP9904485A2 (hu) 2000-08-28
ZA997446B (en) 2001-06-04
HU9904485D0 (en) 2000-02-28

Similar Documents

Publication Publication Date Title
RU2158607C2 (ru) Лечение артериосклероза и ксантомы
US6066653A (en) Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
JP6189918B2 (ja) 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
KR100592842B1 (ko) 알츠하이머병의 치료 방법
JP2010155866A (ja) 高脂質血症および関連疾患の処置のための置換シアノピロリジンの使用およびそれらを含む組み合わせ製剤
PT97806A (pt) Processo para a preparacao de composicoes farmaceuticas contendo pravastatina utilizadas para prevenir a manifestacao de reestenose apos angioplastia
US4931430A (en) Method for preventing or treating anxiety employing an ACE inhibitor
JPH04226921A (ja) アテローム性動脈硬化の予防、安定または後退用医薬組成物
CA2291471A1 (fr) Diminution des concentrations de lipoproteine(a) dans le sang
US5212165A (en) Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
CA2026686A1 (fr) Methode de prevention de l'apparition du diabete de type 11 par l'emploi d'un inhibiteur de l'enzyme de conversion
AU727895B2 (en) Method for treating atherosclerosis with an MPT inhibitor and cholesterol lowering drugs
NZ546162A (en) Therapeutic treatment
PT92988A (pt) Processo para a preparacao duma composicao para tratar a dependencia de uma droga de abuso empregando um inibidor do enzima que converte a angiotensina
AU6304999A (en) Lowering blood levels of lipoprotein(a)
USH734H (en) Method for inhibiting onset of or treating migraine headaches employing an ACE inhibitor
JP2008530153A (ja) マニジピンおよびスタチンの治療における組み合わせ
CA2007525A1 (fr) Methode pour faciliter l'obeissance a un regime alimentaire par l'emploi d'un inhibiteur de l'enzyme de conversion de l'angiotensine
AU2008201290B2 (en) Therapeutic treatment
US6630502B2 (en) Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
EP0334264A2 (fr) Compositions pharmaceutiques pour le traitement de dyscinesies tardives contenant un inhibiteur de liace
CA2050042A1 (fr) Methode de prevention et de traitement de l'anxiete alliant un inhibiteur de l'enzyme de conversion de l'angiotensine et un medicament agissant sur les recepteurs de la

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued